BVS Overview

Bioventus Inc. is a medical device company. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. It offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery.

Wall Street analysts forecast BVS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BVS is14.00 USD with a low forecast of 13.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Bioventus Inc revenue for the last quarter amounts to 157.90M USD, increased 2.77

Bioventus Inc. EPS for the last quarter amounts to 0.21 USD, decreased -2200.00

Bioventus Inc (BVS) has 930 emplpoyees as of March 22 2026.

Today BVS has the market capitalization of 718.46M USD.